Phase 1 N=16 Does Single Dose Imipramine Affect the Opening Pressure of the Urethral and Anal Sphincter?
Urinary Incontinence, Stress · Fecal Incontinence
Primary: Urethral Opening Pressure (UOP) — 2.90411; -3.623431 cmH2O — p=0.07
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=68 Safety and Pharmacokinetic Study of Y242 in Adult Subjects
Obesity
Primary: Number of Participants Who Experienced Treatment Emergent Adverse Events (TEAEs) — 0; 3; 6; 6 Participants
Phase 1 N=19 Single Dose Crossover Study to Compare the Respiratory Drive After Administration of Belbuca, Oxycodone and Placebo.
Respiratory Depression
Primary: Respiratory Drive — 23957.34; 22460.95; 23626.79; 21577.15 mL/min
Phase 1 N=44 A Comparative Study of New Formulation and Approved Formulation for Levothyroxine in Healthy Volunteers
Healthy
Primary: Maximum Serum Concentration in Pre Dose Corrected Data (Cmax[aj]) of Levothyroxine (T4) — 67.24; 66.44 nanogram per milliliter (ng/mL)
Phase 1 N=30 Phase 1 Novel Live Attenuated Serotype 2 Oral Polio Vaccine Study in Inactivated Polio Vaccine (IPV) Primed Adults
Poliomyelitis
Primary: Number of Participants With Serious Adverse Events and Severe Adverse Events Throughout the Study — 0; 0; 6; 9 Participants
Phase 1 N=23 Fecal Microbiota Transplantation in Pediatric Patients
Inflammatory Bowel Diseases (IBD) · Crohn's Disease (CD) · Ulcerative Colitis (UC)
Primary: Number of Occurrences of Adverse Events at 6 Months According to Adverse Event Term — 11; 5; 5; 3 Events
Phase 1 N=49 A Pharmacokinetic Study Comparing MB02 And EU Avastin® In Healthy Male Volunteers
Healthy Volunteers · Male · Japanese
Primary: Area Under the Serum Concentration-time Curve From Time Zero to Infinity [AUC(0-∞)] — 30200000; 29000000 ng*h/mL
Phase 1 N=74 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of GS-5745 (Andecaliximab) in Adults With Moderate to Severe Active Ulcerative Colitis
Ulcerative Colitis
Primary: Percentage of Participants Who Experienced Any Treatment-Emergent Adverse Events (TEAEs) (SAD/MAD) — 0.0; 20.0; 20.0; 60.0 percentage of participants
Phase 1 N=14 Nintedanib and Weekly Docetaxel in Lung Adenocarcinoma
Carcinoma, Non-Small-Cell Lung
Primary: Maximum Tolerated Dose (MTD) of Nintedanib Administered in Combination With Docetaxel — NA milligram
Phase 1 N=90 Study to Evaluate the Safety and Tolerability of Tirabrutinib (ONO/GS-4059) Given as Monotherapy in Participants With Relapsed/Refractory NHL and CLL
Non Hodgkins Lymphoma · Chronic Lymphocytic Leukaemia
Primary: Percentage of Participants Experiencing Dose-Limiting Toxicities — 0.0; 0.0; 0.0; 0.0 percentage of participants
Phase 1 N=11 Cytomegalovirus (CMV) RNA-Pulsed Dendritic Cells for Pediatric Patients and Young Adults With WHO Grade IV Glioma, Recurrent Malignant Glioma, or Recurrent Medulloblastoma
Glioblastoma · Malignant Glioma · Medulloblastoma Recurrent
Primary: Percentage of Patients for Whom 3 or More Vaccines Can be Made — 90.9 percentage of participants
Phase 1 N=12 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 986 Administered Orally to Healthy Volunteers and Participants With Severely Impaired Renal Function
Heart Failure
Primary: AMG 986 Pharmacokinetic (PK) Parameter: Area Under the Plasma Concentration Time Curve From Time 0 to the Time of the Last Quantifiable Sample (AUClast) — 80,000; 64,500…
Phase 1 N=15 Immunization With NY-ESO-1 Protein Combined With CpG 7909 in Patients With Prostate Cancer
Prostate Cancer
Primary: Number of Patients With Treatment-emergent Adverse Events (TEAEs) — 15; 2; 10; 2 Participants
Phase 1 N=25 Phase I Dose Escalation Trial of Efavirenz in Solid Tumours or Non-Hodgkin Lymphoma in Therapeutic Failure.
Solid Tumors · Non-Hodgkin's Lymphoma
Primary: Maximum Tolerated Dose (MTD) of Efavirenz — 1200 mg
Phase 1 N=21 Altering Memories That Increase Risk of Relapse in Alcohol Use Disorders
Alcohol Use Disorder · Alcohol Dependence
Primary: Evaluate Safety of a Single 15 mg Dose of Rapamycin (Sirolimus) at First Visit. — 0; 3 Participants